CompletedNot Applicable

Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair Loss

Italy240 participantsStarted 2024-11-04

Plain-language summary

The goal of this study was to learn if dietary supplement in capsules and drinkable works to help hair loss in volunteers with chronic telogen effluvium and androgenetic alopecia and learn about its safety. The main questions it aims to answer are: * Does dietary supplement in capsules and drinkable reduces hair loss in women and men suffering from chronic telogen effluvium or androgenetic alopecia? * Were the products well accepted by the subjects from their´s perspective? Researchers will compare dietary supplement in capsules and drinkable to a placebo (a look-alike substance that contains no active ingredients) to see if dietary supplements works to reduce hair loss. Participants will: * Take assigned diatry supplement in capsule or drinkable or a placebo every day for 6 months * Visit the study facility once every 3 months for evaulations * Keep a diary of the product use

Who can participate

Age range

18 Years – 62 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy female and male subjects, including at least 70% female subjects aged over 30 years old ✓ Caucasian ethnicity * Aged between 18 and 62 years old (extreme included) * 50% of subjects with chronic telogen effluvium (stage from 2 to 4, according to Sinclair scale for female pattern hair loss in women and modified Sinclair scale for female pattern hair loss in men) * 50% of subjects with androgenetic alopecia (AGA): female subjects Ludwig scale (score I-II) and male subjects Hamilton- Norwood scale (vertex II-III) * Subjects aware of the study procedures and having signed an informed consent form * Subjects registered with National Health Service (NHS) * Subjects certifying the truthfulness of the personal data disclosed to the investigator * Subjects able to understand the language used in the investigation and to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements * The pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) should be stable for at least one month without any changes expected or planned during the study * Commitment not to change the daily routine or the lifestyle * Subject informed about the study procedures and having signed the privacy policy Exclusion Criteria: * Subjects who do not fit the inclusion criteria. * Subjects with acute or chronic diseases able to interfere with the outcome of the study or that are con…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change from Baseline in the hair density at 3 and 6 months

Timeframe: From the baseline, at 3 months and at the end of the study (6 months).

Trial details

NCT IDNCT07358403

SponsorLacer S.A.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-09-26

View on ClinicalTrials.gov More Androgenetic Alopecia (AGA) trials